PET/CT is a critical tool for MM staging, treatment response monitoring, and the detection of extramedullary disease (EMD), the authors explained. PET/CT has also been found to be a valuable ...

Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for relapsed/refractory multiple myeloma.

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

As patients with multiple myeloma may develop extramedullary lesions and the distribution of lesions in the bone marrow is not uniform, whole-body imaging studies are necessary to determine treatment ...

Bone lesions are a highly prevalent and debilitating disease-defining feature of multiple myeloma (MM) with more than 80% of patients developing them during their disease course. 1 These skeletal ...

We report phase I trial results for pasritamig, a first-in-class, T-cell–engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cancer (PC) cells.

Cemsidomide led to strong responses at multiple doses in patients with multiple myeloma, including one complete response with no minimal residual disease detected.